These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33246970)

  • 1. Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke.
    Wu S; Mair G; Cohen G; Morris Z; von Heijne A; Bradey N; Cala L; Peeters A; Farrall AJ; Adami A; Potter G; Liu M; Lindley RI; Sandercock PAG; Wardlaw JM;
    Stroke Vasc Neurol; 2021 Jun; 6(2):238-243. PubMed ID: 33246970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
    IST-3 collaborative group
    Lancet Neurol; 2015 May; 14(5):485-96. PubMed ID: 25819484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
    Mair G; von Kummer R; Morris Z; von Heijne A; Bradey N; Cala L; Peeters A; Farrall AJ; Adami A; Potter G; Cohen G; Sandercock PA; Lindley RI; Wardlaw JM;
    Neurology; 2016 Jan; 86(2):118-25. PubMed ID: 26658907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
    Robinson TG; Wang X; Arima H; Bath PM; Billot L; Broderick JP; Demchuk AM; Donnan GA; Kim JS; Lavados PM; Lee TH; Lindley RI; Martins SCO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Nguyen TH; Wang JG; Woodward M; Chalmers J; Anderson CS;
    Stroke; 2017 Jul; 48(7):1877-1883. PubMed ID: 28619989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
    Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D;
    N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.
    Bracard S; Ducrocq X; Mas JL; Soudant M; Oppenheim C; Moulin T; Guillemin F;
    Lancet Neurol; 2016 Oct; 15(11):1138-47. PubMed ID: 27567239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
    Thomalla G; Simonsen CZ; Boutitie F; Andersen G; Berthezene Y; Cheng B; Cheripelli B; Cho TH; Fazekas F; Fiehler J; Ford I; Galinovic I; Gellissen S; Golsari A; Gregori J; Günther M; Guibernau J; Häusler KG; Hennerici M; Kemmling A; Marstrand J; Modrau B; Neeb L; Perez de la Ossa N; Puig J; Ringleb P; Roy P; Scheel E; Schonewille W; Serena J; Sunaert S; Villringer K; Wouters A; Thijs V; Ebinger M; Endres M; Fiebach JB; Lemmens R; Muir KW; Nighoghossian N; Pedraza S; Gerloff C;
    N Engl J Med; 2018 Aug; 379(7):611-622. PubMed ID: 29766770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
    Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W;
    Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
    Ma H; Campbell BCV; Parsons MW; Churilov L; Levi CR; Hsu C; Kleinig TJ; Wijeratne T; Curtze S; Dewey HM; Miteff F; Tsai CH; Lee JT; Phan TG; Mahant N; Sun MC; Krause M; Sturm J; Grimley R; Chen CH; Hu CJ; Wong AA; Field D; Sun Y; Barber PA; Sabet A; Jannes J; Jeng JS; Clissold B; Markus R; Lin CH; Lien LM; Bladin CF; Christensen S; Yassi N; Sharma G; Bivard A; Desmond PM; Yan B; Mitchell PJ; Thijs V; Carey L; Meretoja A; Davis SM; Donnan GA;
    N Engl J Med; 2019 May; 380(19):1795-1803. PubMed ID: 31067369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
    Thomalla G; Boutitie F; Ma H; Koga M; Ringleb P; Schwamm LH; Wu O; Bendszus M; Bladin CF; Campbell BCV; Cheng B; Churilov L; Ebinger M; Endres M; Fiebach JB; Fukuda-Doi M; Inoue M; Kleinig TJ; Latour LL; Lemmens R; Levi CR; Leys D; Miwa K; Molina CA; Muir KW; Nighoghossian N; Parsons MW; Pedraza S; Schellinger PD; Schwab S; Simonsen CZ; Song SS; Thijs V; Toni D; Hsu CY; Wahlgren N; Yamamoto H; Yassi N; Yoshimura S; Warach S; Hacke W; Toyoda K; Donnan GA; Davis SM; Gerloff C;
    Lancet; 2020 Nov; 396(10262):1574-1584. PubMed ID: 33176180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial.
    Delcourt C; Wang X; Zhou Z; Wardlaw JM; Mair G; Robinson TG; Chen X; Yoshimura S; Torii-Yoshimura T; Carcel C; Calic Z; Tan WY; Malavera A; Anderson CS; Lindley RI
    J Neurol Neurosurg Psychiatry; 2020 Dec; 91(12):1290-1296. PubMed ID: 33055145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Deterioration and Early Imaging Changes after Intravenous Tissue Plasminogen Activator Administration in Acute Ischemic Stroke Patients.
    Chou C; Bourekas EC; Slivka A
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1823-1827. PubMed ID: 27133771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment.
    Ospel JM; Menon BK; Demchuk AM; Almekhlafi MA; Kashani N; Mayank A; Fainardi E; Rubiera M; Khaw A; Shankar JJ; Dowlatshahi D; Puig J; Sohn SI; Ahn SH; Poppe A; Calleja A; Hill MD; Goyal M
    Stroke; 2020 Nov; 51(11):3232-3240. PubMed ID: 33070714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
    Ohta T; Okada K; Fukuda M; Masahira N; Matsuoka T; Tsuno T; Takemura M
    J Stroke Cerebrovasc Dis; 2018 Jul; 27(7):1844-1851. PubMed ID: 29555402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase.
    Hirano T; Sasaki M; Tomura N; Ito Y; Kobayashi S;
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):898-902. PubMed ID: 21737309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intravenous alteplase on ischaemic lesion water homeostasis.
    Broocks G; Kniep H; Kemmling A; Flottmann F; Nawabi J; Elsayed S; Schön G; Thomalla G; Fiehler J; Hanning U
    Eur J Neurol; 2020 Feb; 27(2):376-383. PubMed ID: 31529738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
    Parsons M; Spratt N; Bivard A; Campbell B; Chung K; Miteff F; O'Brien B; Bladin C; McElduff P; Allen C; Bateman G; Donnan G; Davis S; Levi C
    N Engl J Med; 2012 Mar; 366(12):1099-107. PubMed ID: 22435369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.